Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Meeting abstract

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation

Authors: Xiu-li Wu, Qi-fa Liu

Published in: Journal of Hematology & Oncology | Special Issue 1/2012

Login to get access

Excerpt

Epstein - Barr virus (EBV) is a gamma - herpes virus that infects more 90% of humans. Most EBV primary infections and reactivations are subclinical and require no therapy in immunocompetent people. However, EBV infection or reactivation may result in life-threatening diseases in immunocompromised people [15]. EBV infection and reactivation might be associated with a spectrum of clinical presentations ranging from fever to post-transplant lymphoproliferative diseases (PTLD), including viremia, pneumonia, encephalitis/ myelitis, PTLD, and so on, in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), which arise as a consequence of infected B/T lymphocytes, epithelial cells and neural cells, and they are sustained by EBV latency products [2, 3, 6]. EBV-associated PTLD were only the tip of the iceberg of post-transplant EBV-associated diseases [2], but there is short of large sample data about the incidence of EBV-associated other diseases other than PTLD in recipients of transplants. Kinch et al. reported that 7 of 16 patients with EBV-DNA-emia developed EBV-associated diseases in 39 recipients of allo-HSCT, including 3 PTLD, 1 myelitis, 1 encephalitis and 2 reactivations with fever [7]. In one of our prospective study, 16 of 64 patients with EBV-DNA-emia developed PTLD and 11 patients developed EBV-associated other diseases, including 6 fever, 1 encephalitis, 1 myelitis, 1 pneumonia, 1 encephalitis accompanying pneumonia and 1 enteritis accompanying hepatitis, in 172 recipients of allo-HSCT. The incidence of PTLD in a large study varied from 0.5% to 22% after allo-HSCT, depending on the number of risk factors including T-depleted graft, the use of ATG, unrelated donor, HLA- mismatched, acute / chronic graft versus host disease (GVHD), cytomegavirus (CMV) antigen-emia, and so on [3, 8, 9]. Except for lymph nodes, EBV can also involve nearly all other tissues and organs in recipients of transplants, and isolated central nervous system (CNS) involvement with PTLD is considered to be an exceedingly rare complication after allo-HSCT [10]. But our prospective study showed that 16 of 27 patients with EBV-associated diseases were extranodal involvement and 12 patients developed EBV-associated CNS diseases (6 CNS-PTLD, 5 encephalitis and 1 myelitis). …
Literature
2.
go back to reference Bitan M: Epstein-Barr virus infection after stem cell transplantation: new concepts are needed both for the donor and the recipient. Clin Infect Dis. 2006, 43: 896-897. 10.1086/507032.CrossRefPubMed Bitan M: Epstein-Barr virus infection after stem cell transplantation: new concepts are needed both for the donor and the recipient. Clin Infect Dis. 2006, 43: 896-897. 10.1086/507032.CrossRefPubMed
3.
go back to reference Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP: Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999, 94: 2208-2216.PubMed Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP: Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999, 94: 2208-2216.PubMed
4.
go back to reference Gulley ML, Tang W: Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010, 23: 350-366. 10.1128/CMR.00006-09.PubMedCentralCrossRefPubMed Gulley ML, Tang W: Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010, 23: 350-366. 10.1128/CMR.00006-09.PubMedCentralCrossRefPubMed
5.
go back to reference Styczynski J, Einsele H, Gil L, Ljungman P: Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009, 11: 383-392. 10.1111/j.1399-3062.2009.00411.x.CrossRefPubMed Styczynski J, Einsele H, Gil L, Ljungman P: Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009, 11: 383-392. 10.1111/j.1399-3062.2009.00411.x.CrossRefPubMed
6.
go back to reference Wakiguchi H: Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev Oncol Hematol. 2002, 44: 193-202. 10.1016/S1040-8428(02)00111-7.CrossRefPubMed Wakiguchi H: Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev Oncol Hematol. 2002, 44: 193-202. 10.1016/S1040-8428(02)00111-7.CrossRefPubMed
7.
go back to reference Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K: Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007, 39: 235-244. 10.1080/00365540600978906.CrossRefPubMed Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K: Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007, 39: 235-244. 10.1080/00365540600978906.CrossRefPubMed
8.
go back to reference Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, Wagner JE, Filipovich AH: B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999, 23: 251-258. 10.1038/sj.bmt.1701554.CrossRefPubMed Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, Wagner JE, Filipovich AH: B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999, 23: 251-258. 10.1038/sj.bmt.1701554.CrossRefPubMed
9.
go back to reference Reddy N, Rezvani K, Barrett AJ, Savani BN: Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011, 17: 591-597. 10.1016/j.bbmt.2010.08.007.PubMedCentralCrossRefPubMed Reddy N, Rezvani K, Barrett AJ, Savani BN: Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011, 17: 591-597. 10.1016/j.bbmt.2010.08.007.PubMedCentralCrossRefPubMed
10.
go back to reference Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC: Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant. 2007, 39: 249-251. 10.1038/sj.bmt.1705575.CrossRefPubMed Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC: Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant. 2007, 39: 249-251. 10.1038/sj.bmt.1705575.CrossRefPubMed
11.
go back to reference Styczynski J, Gil L, Ljungman P, Einsele H: Strategy of pre-emptive management of EBV-related post-transplant lymphoproliferative disorder: results of the IDWP-EBMT 2009 Survey. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation. 2010, Oral Session 7 Styczynski J, Gil L, Ljungman P, Einsele H: Strategy of pre-emptive management of EBV-related post-transplant lymphoproliferative disorder: results of the IDWP-EBMT 2009 Survey. 36th Annual Meeting of the European Group for Blood and Marrow Transplantation. 2010, Oral Session 7
12.
go back to reference Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC: Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis. 2011, 13: 524-530. 10.1111/j.1399-3062.2011.00621.x.CrossRefPubMed Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC: Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis. 2011, 13: 524-530. 10.1111/j.1399-3062.2011.00621.x.CrossRefPubMed
13.
go back to reference Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T: Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol. 2011, 94: 495-498. 10.1007/s12185-011-0951-3.CrossRefPubMed Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T: Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol. 2011, 94: 495-498. 10.1007/s12185-011-0951-3.CrossRefPubMed
14.
go back to reference Tang J-L, Yao M, Lu M-Y, Ko B-S, Huang S-Y, Li C-C, Lin C-T, Hou H-A, Wu S-J, Chou W-C: Quantitative Monitoring of EBV Viral Load in 222 Hematopoietic Stem Cell Transplant Patients: Risk Analysis and Development of EBV-Associated Post-Transplant Lymphoproliferative Diseases (PTLD). ASH Annual Meeting Abstracts. 2011, 118: 3018- Tang J-L, Yao M, Lu M-Y, Ko B-S, Huang S-Y, Li C-C, Lin C-T, Hou H-A, Wu S-J, Chou W-C: Quantitative Monitoring of EBV Viral Load in 222 Hematopoietic Stem Cell Transplant Patients: Risk Analysis and Development of EBV-Associated Post-Transplant Lymphoproliferative Diseases (PTLD). ASH Annual Meeting Abstracts. 2011, 118: 3018-
15.
go back to reference Petropoulou AD, Porcher R, de Latour RP, Xhaard A, Ribaud P, Socie G, Robin M: Pre-Emptive Rituximab Treatment for Epstein-Barr Virus (EBV) Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): High Incidence of Infections and Delayed Immune Reconstitution. ASH Annual Meeting Abstracts. 2011, 116: 2303- Petropoulou AD, Porcher R, de Latour RP, Xhaard A, Ribaud P, Socie G, Robin M: Pre-Emptive Rituximab Treatment for Epstein-Barr Virus (EBV) Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): High Incidence of Infections and Delayed Immune Reconstitution. ASH Annual Meeting Abstracts. 2011, 116: 2303-
16.
go back to reference Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M, Messina C: A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation. 2010, 89: 1533-1540. 10.1097/TP.0b013e3181dd6c0a.CrossRefPubMed Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M, Messina C: A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation. 2010, 89: 1533-1540. 10.1097/TP.0b013e3181dd6c0a.CrossRefPubMed
17.
go back to reference Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE: CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000, 95: 1502-1505.PubMed Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE: CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000, 95: 1502-1505.PubMed
18.
go back to reference Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N: The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011, 25: 1-6. 10.1038/leu.2010.224.CrossRefPubMed Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N: The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011, 25: 1-6. 10.1038/leu.2010.224.CrossRefPubMed
19.
go back to reference Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E: Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001, 115: 112-118. 10.1046/j.1365-2141.2001.03041.x.CrossRefPubMed Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, Vilmer E: Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001, 115: 112-118. 10.1046/j.1365-2141.2001.03041.x.CrossRefPubMed
20.
go back to reference Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010, 115: 925-935. 10.1182/blood-2009-08-239186.PubMedCentralCrossRefPubMed Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010, 115: 925-935. 10.1182/blood-2009-08-239186.PubMedCentralCrossRefPubMed
Metadata
Title
Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
Authors
Xiu-li Wu
Qi-fa Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue Special Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-S1-A8

Other articles of this Special Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine